Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 93 entries
Sorted by: Best Match Show Resources per page
NICE to set out how it will judge social benefits of drugs.

BMJ (Clinical research ed.)

Hawkes N.
PMID: 24445857
BMJ. 2014 Jan 20;348:g370. doi: 10.1136/bmj.g370.

No abstract available.

Cite
Hawkes N. NICE to set out how it will judge social benefits of drugs. BMJ. 2014;348:g370doi: 10.1136/bmj.g370.
Hawkes, N. (2014). NICE to set out how it will judge social benefits of drugs. BMJ (Clinical research ed.), 348g370. https://doi.org/10.1136/bmj.g370
Hawkes, Nigel. "NICE to set out how it will judge social benefits of drugs." BMJ (Clinical research ed.) vol. 348 (2014): g370. doi: https://doi.org/10.1136/bmj.g370
Hawkes N. NICE to set out how it will judge social benefits of drugs. BMJ. 2014 Jan 20;348:g370. doi: 10.1136/bmj.g370. PMID: 24445857.
Copy Download .nbib Format: NLM
Shire gobbles up Lumena and its fatty liver pills.

Nature biotechnology

Sinha G.
PMID: 25101725
Nat Biotechnol. 2014 Aug;32(8):705. doi: 10.1038/nbt0814-705.

No abstract available.

Cite
Sinha G. Shire gobbles up Lumena and its fatty liver pills. Nat Biotechnol. 2014;32(8):705doi: 10.1038/nbt0814-705.
Sinha, G. (2014). Shire gobbles up Lumena and its fatty liver pills. Nature biotechnology, 32(8), 705. https://doi.org/10.1038/nbt0814-705
Sinha, Gunjan. "Shire gobbles up Lumena and its fatty liver pills." Nature biotechnology vol. 32,8 (2014): 705. doi: https://doi.org/10.1038/nbt0814-705
Sinha G. Shire gobbles up Lumena and its fatty liver pills. Nat Biotechnol. 2014 Aug;32(8):705. doi: 10.1038/nbt0814-705. PMID: 25101725.
Copy Download .nbib Format: NLM
Capsule Commentary on Duru, et al., potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) Study.

Journal of general internal medicine

Evans DV.
PMID: 24026417
J Gen Intern Med. 2014 Jan;29(1):185. doi: 10.1007/s11606-013-2561-7.

No abstract available.

Cite
Evans DV. Capsule Commentary on Duru, et al., potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) Study. J Gen Intern Med. 2014;29(1):185doi: 10.1007/s11606-013-2561-7.
Evans, D. V. (2014). Capsule Commentary on Duru, et al., potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) Study. Journal of general internal medicine, 29(1), 185. https://doi.org/10.1007/s11606-013-2561-7
Evans, David V. "Capsule Commentary on Duru, et al., potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) Study." Journal of general internal medicine vol. 29,1 (2014): 185. doi: https://doi.org/10.1007/s11606-013-2561-7
Evans DV. Capsule Commentary on Duru, et al., potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) Study. J Gen Intern Med. 2014 Jan;29(1):185. doi: 10.1007/s11606-013-2561-7. PMID: 24026417; PMCID: PMC3889940.
Copy Download .nbib Format: NLM
Prices of pharmaceuticals in poor countries are much lower than in wealthy countries.

Health affairs (Project Hope)

Schweitzer SO, Comanor WS.
PMID: 21821573
Health Aff (Millwood). 2011 Aug;30(8):1553-61. doi: 10.1377/hlthaff.2009.0923.

Keeping pharmaceuticals affordable in poor countries is important for public health. Economic models suggest that manufacturers should be able to charge substantially lower prices in those markets than in industrialized countries without drastically reducing their profits. We report the...

Cite
Schweitzer SO, Comanor WS. Prices of pharmaceuticals in poor countries are much lower than in wealthy countries. Health Aff (Millwood). 2011;30(8):1553-61doi: 10.1377/hlthaff.2009.0923.
Schweitzer, S. O., & Comanor, W. S. (2011). Prices of pharmaceuticals in poor countries are much lower than in wealthy countries. Health affairs (Project Hope), 30(8), 1553-61. https://doi.org/10.1377/hlthaff.2009.0923
Schweitzer, Stuart O, and Comanor, William S. "Prices of pharmaceuticals in poor countries are much lower than in wealthy countries." Health affairs (Project Hope) vol. 30,8 (2011): 1553-61. doi: https://doi.org/10.1377/hlthaff.2009.0923
Schweitzer SO, Comanor WS. Prices of pharmaceuticals in poor countries are much lower than in wealthy countries. Health Aff (Millwood). 2011 Aug;30(8):1553-61. doi: 10.1377/hlthaff.2009.0923. PMID: 21821573.
Copy Download .nbib Format: NLM
Trade talks between US and EU could increase cost of drugs, new report says.

BMJ (Clinical research ed.)

Cohen D.
PMID: 24671989
BMJ. 2014 Mar 26;348:g2402. doi: 10.1136/bmj.g2402.

No abstract available.

Cite
Cohen D. Trade talks between US and EU could increase cost of drugs, new report says. BMJ. 2014;348:g2402doi: 10.1136/bmj.g2402.
Cohen, D. (2014). Trade talks between US and EU could increase cost of drugs, new report says. BMJ (Clinical research ed.), 348g2402. https://doi.org/10.1136/bmj.g2402
Cohen, Deborah. "Trade talks between US and EU could increase cost of drugs, new report says." BMJ (Clinical research ed.) vol. 348 (2014): g2402. doi: https://doi.org/10.1136/bmj.g2402
Cohen D. Trade talks between US and EU could increase cost of drugs, new report says. BMJ. 2014 Mar 26;348:g2402. doi: 10.1136/bmj.g2402. PMID: 24671989.
Copy Download .nbib Format: NLM
Cost-effective drug therapy.

Healthcare executive

McGhan WF.
PMID: 10126748
Healthc Exec. 1993 Jul-Aug;8(4):27.

No abstract available.

Cite
McGhan WF. Cost-effective drug therapy. Healthc Exec. 1993;8(4):27
McGhan, W. F. (1993). Cost-effective drug therapy. Healthcare executive, 8(4), 27.
McGhan, W F. "Cost-effective drug therapy." Healthcare executive vol. 8,4 (1993): 27.
McGhan WF. Cost-effective drug therapy. Healthc Exec. 1993 Jul-Aug;8(4):27. PMID: 10126748.
Copy Download .nbib Format: NLM
The future research agenda. A view from the pharmaceutical industry.

PharmacoEconomics

Barr C.
PMID: 10155587
Pharmacoeconomics. 1994;6:61-2. doi: 10.2165/00019053-199400061-00014.

As a responsible partner in healthcare systems, the pharmaceutical industry hopes to see a research agenda on pharmaceutical issues that will provide more information on trends in healthcare reform affecting medicines. Urgent questions include whether some forms of cost...

Cite
Barr C. The future research agenda. A view from the pharmaceutical industry. Pharmacoeconomics. 1994;6:61-2doi: 10.2165/00019053-199400061-00014.
Barr, C. (1994). The future research agenda. A view from the pharmaceutical industry. PharmacoEconomics, 661-2. https://doi.org/10.2165/00019053-199400061-00014
Barr, C. "The future research agenda. A view from the pharmaceutical industry." PharmacoEconomics vol. 6 (1994): 61-2. doi: https://doi.org/10.2165/00019053-199400061-00014
Barr C. The future research agenda. A view from the pharmaceutical industry. Pharmacoeconomics. 1994;6:61-2. doi: 10.2165/00019053-199400061-00014. PMID: 10155587.
Copy Download .nbib Format: NLM
Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry.

PharmacoEconomics

Thomas LG.
PMID: 10155588
Pharmacoeconomics. 1994;6:67-70. doi: 10.2165/00019053-199400061-00016.

This paper examines the nature of Japanese government regulation of pharmaceutical prices, and the impact of that regulation on the competitive performance of the Japanese industry. Possible implications for the reintroduction of pharmaceutical price controls in the US are...

Cite
Thomas LG. Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry. Pharmacoeconomics. 1994;6:67-70doi: 10.2165/00019053-199400061-00016.
Thomas, L. G. (1994). Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry. PharmacoEconomics, 667-70. https://doi.org/10.2165/00019053-199400061-00016
Thomas, L G. "Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry." PharmacoEconomics vol. 6 (1994): 67-70. doi: https://doi.org/10.2165/00019053-199400061-00016
Thomas LG. Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry. Pharmacoeconomics. 1994;6:67-70. doi: 10.2165/00019053-199400061-00016. PMID: 10155588.
Copy Download .nbib Format: NLM
'The pros and cons of a single euro-price for drugs' and 'the economics of parallel trade'.

PharmacoEconomics

Rovira J.
PMID: 10182191
Pharmacoeconomics. 1998 Jul;14(1):135-7. doi: 10.2165/00019053-199814010-00010.

No abstract available.

Cite
Rovira J. 'The pros and cons of a single euro-price for drugs' and 'the economics of parallel trade'. Pharmacoeconomics. 1998;14(1):135-7doi: 10.2165/00019053-199814010-00010.
Rovira, J. (1998). 'The pros and cons of a single euro-price for drugs' and 'the economics of parallel trade'. PharmacoEconomics, 14(1), 135-7. https://doi.org/10.2165/00019053-199814010-00010
Rovira, J. "'The pros and cons of a single euro-price for drugs' and 'the economics of parallel trade'." PharmacoEconomics vol. 14,1 (1998): 135-7. doi: https://doi.org/10.2165/00019053-199814010-00010
Rovira J. 'The pros and cons of a single euro-price for drugs' and 'the economics of parallel trade'. Pharmacoeconomics. 1998 Jul;14(1):135-7. doi: 10.2165/00019053-199814010-00010. PMID: 10182191.
Copy Download .nbib Format: NLM
Low osmolar contrast media: a quality and cost dilemma.

College review (Denver, Colo.)

Ostrander JR.
PMID: 10121945
Coll Rev. 1992;9(2):25-39.

As a medical group manager, cost/benefit decisions will not often be yours to make alone. But your participation--especially on cost, reimbursement and legal matters--can be valuable. It should be presented in a thorough and factual manner. Your role in...

Cite
Ostrander JR. Low osmolar contrast media: a quality and cost dilemma. Coll Rev. 1992;9(2):25-39
Ostrander, J. R. (1992). Low osmolar contrast media: a quality and cost dilemma. College review (Denver, Colo.), 9(2), 25-39.
Ostrander, J R. "Low osmolar contrast media: a quality and cost dilemma." College review (Denver, Colo.) vol. 9,2 (1992): 25-39.
Ostrander JR. Low osmolar contrast media: a quality and cost dilemma. Coll Rev. 1992;9(2):25-39. PMID: 10121945.
Copy Download .nbib Format: NLM
Impact of Brexit on UK and EU Drug Regulation and Patient Access.

Clinical pharmacology and therapeutics

Breckenridge A, Feldschreiber P.
PMID: 30346627
Clin Pharmacol Ther. 2019 Apr;105(4):923-925. doi: 10.1002/cpt.1261. Epub 2018 Nov 22.

The chronology of the United Kingdom (UK) leaving the European Union (EU) is presented together with its implications for medicines regulation, including the move of the European Medicines Agency from London (UK) to Amsterdam (the Netherlands). The legal and...

Cite
Breckenridge A, Feldschreiber P. Impact of Brexit on UK and EU Drug Regulation and Patient Access. Clin Pharmacol Ther. 2018;105(4):923-925doi: 10.1002/cpt.1261.
Breckenridge, A., & Feldschreiber, P. (2019). Impact of Brexit on UK and EU Drug Regulation and Patient Access. Clinical pharmacology and therapeutics, 105(4), 923-925. https://doi.org/10.1002/cpt.1261
Breckenridge, Alasdair, and Feldschreiber, Peter. "Impact of Brexit on UK and EU Drug Regulation and Patient Access." Clinical pharmacology and therapeutics vol. 105,4 (2019): 923-925. doi: https://doi.org/10.1002/cpt.1261
Breckenridge A, Feldschreiber P. Impact of Brexit on UK and EU Drug Regulation and Patient Access. Clin Pharmacol Ther. 2019 Apr;105(4):923-925. doi: 10.1002/cpt.1261. Epub 2018 Nov 22. PMID: 30346627.
Copy Download .nbib Format: NLM
Prescription Drug Pricing.

Annals of emergency medicine

[No authors listed]
PMID: 30236349
Ann Emerg Med. 2018 Oct;72(4):e59. doi: 10.1016/j.annemergmed.2018.07.029.

No abstract available.

Cite
Prescription Drug Pricing. Ann Emerg Med. 2018;72(4):e59doi: 10.1016/j.annemergmed.2018.07.029.
(2018). Prescription Drug Pricing. Annals of emergency medicine, 72(4), e59. https://doi.org/10.1016/j.annemergmed.2018.07.029
"Prescription Drug Pricing." Annals of emergency medicine vol. 72,4 (2018): e59. doi: https://doi.org/10.1016/j.annemergmed.2018.07.029
Prescription Drug Pricing. Ann Emerg Med. 2018 Oct;72(4):e59. doi: 10.1016/j.annemergmed.2018.07.029. PMID: 30236349.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 93 entries